Bernard S. Buetow
Bernard S. Buetow has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Trageser
Oncology R&D, Pfizer Worldwide Research, San Diego, California
23 shared publications - Amy Jackson-Fisher
10Translational Oncology, Pfizer Inc., San Diego, California
23 shared publications - Anand Giddabasappa
Animal Models and Imaging, Comparative Medicine-Drug Safety R&D, Pfizer Inc, United States
23 shared publications - Andrea T. Hooper
14 Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA
23 shared publications - Ashley Thomas
Oncology R&D, Pfizer Worldwide Research, San Diego, California
23 shared publications - Changhua Ji
Affiliation Drug Safety Research and Development, Pfizer Inc, San Diego, California, United States of America
23 shared publications
Latest Publications
- 30 December 2025
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 54 (3) , 233-266
Scientific and Regulatory Policy Committee Points to Consider*: Sample Selection, Assay Design, Data Generation and Interpretation, and Reporting Practices for Chromogenic Immunohistochemical (IHC) Assays in Nonclinical Drug Development
Chromogenic immunohistochemistry (IHC) is an important molecular localization assay in biomedical research and nonclinical drug development, enabling the visualization of specific epitopes within tissues. The methodology is widely used in drug target selection, risk assessment, understanding disease biology, and characterizing histopathological findings in nonclinical studies. The Scientific and Regulatory Policy Committee of the Society of Toxicologic Pathology formed a working group to compile essential information on chromogenic IHC assays not performed in compliance with Good Laboratory Practice (GLP) from nonclinical studies, using relevant literature and the Working Group members’ collective expertise. In this “Points to Consider” article, emphasis is placed on factors influencing IHC data quality, including sample selection, general assay considerations, data generation and interpretation, and effective reporting. The Working Group members deliberated extensively on pertinent topics, aiming to provide specific and practical guidance for pathologists, histologists, and allied scientists engaged in chromogenic IHC assays. While refraining from an exhaustive exploration of the intricate technical details associated with chromogenic IHC, this article offers insights to enhance the accuracy, credibility, and reproducibility of chromogenic IHC, thereby facilitating informed decision-making in the nonclinical development of biomedical products.
- 30 December 2025
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 54 (3) , 233-266
Scientific and Regulatory Policy Committee Points to Consider*: Sample Selection, Assay Design, Data Generation and Interpretation, and Reporting Practices for Chromogenic Immunohistochemical (IHC) Assays in Nonclinical Drug Development
Chromogenic immunohistochemistry (IHC) is an important molecular localization assay in biomedical research and nonclinical drug development, enabling the visualization of specific epitopes within tissues. The methodology is widely used in drug target selection, risk assessment, understanding disease biology, and characterizing histopathological findings in nonclinical studies. The Scientific and Regulatory Policy Committee of the Society of Toxicologic Pathology formed a working group to compile essential information on chromogenic IHC assays not performed in compliance with Good Laboratory Practice (GLP) from nonclinical studies, using relevant literature and the Working Group members’ collective expertise. In this “Points to Consider” article, emphasis is placed on factors influencing IHC data quality, including sample selection, general assay considerations, data generation and interpretation, and effective reporting. The Working Group members deliberated extensively on pertinent topics, aiming to provide specific and practical guidance for pathologists, histologists, and allied scientists engaged in chromogenic IHC assays. While refraining from an exhaustive exploration of the intricate technical details associated with chromogenic IHC, this article offers insights to enhance the accuracy, credibility, and reproducibility of chromogenic IHC, thereby facilitating informed decision-making in the nonclinical development of biomedical products.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-CRX-11201 in vivo model %TGI vs. vehicle at D7
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-CRX-11201 in vivo model %TGI vs. vehicle at D7
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
HCC-1954 in vivo model %TGI vs. vehicle at D16
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
HCC-1954 in vivo model %TGI vs. vehicle at D16
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
MDA-MB-468 in vivo model %TGI vs. vehicle at D19
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
MDA-MB-468 in vivo model %TGI vs. vehicle at D19
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
B7-H4 expression quantification in human breast cancer cell lines by flow cytometry
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
B7-H4 expression quantification in human breast cancer cell lines by flow cytometry
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-BRX-26305 in vivo model %TGI vs. vehicle at D17
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-BRX-26305 in vivo model %TGI vs. vehicle at D17
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
E0771-hB7-H4 /hCD3e in vivo model %TGI vs. vehicle at D42
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
E0771-hB7-H4 /hCD3e in vivo model %TGI vs. vehicle at D42
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
EC50 of PF-07260437 in inducing redirected T cell killing in vitro in cell lines expressing various levels of B7-H4
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
EC50 of PF-07260437 in inducing redirected T cell killing in vitro in cell lines expressing various levels of B7-H4
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
MX-1-luc in vivo model %TGI vs. vehicle at D24
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
MX-1-luc in vivo model %TGI vs. vehicle at D24
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
B7-H4 expression as a percentage of cells with a particular H-Score
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
B7-H4 expression as a percentage of cells with a particular H-Score